The list of 2023 "Outstanding Biotechnology Industry Award" is released! Cross-field industry awards for new medical drugs and immunotherapy demonstrate Taiwan's biotech R&D energy
The list of 2023 “Outstanding Biotechnology Industry Award” is released! Award-winning new biotech drugs and immunotherapy demonstrate R&D energy
The Taiwan Bio-Industry Development Association announced the winners of the “2023 Taiwan BIO Awards Outstanding Biotech Industry Award” on July 18. After three months of preliminary review, re-examination and final review, a total of 13 institutions and product technologies were selected. Chairman Wu Zhongxun said that the “Taiwan BIO Awards Outstanding Biotechnology Industry Award” held annually by the Biotechnology Industry Association was held simultaneously at the BIO Asia-Taiwan Asian Biotechnology Conference and the award ceremony was announced. It was received and encouraged by the President, which affirmed that there has been outstanding development. company, and explore potential stars of tomorrow, hoping to use this to drive the energy of the biotech industry.
The award-winning companies in the past have performed extremely well and have actual performance capabilities in international competition and market expansion. Every year, they can also be selected from the list of candidates and winners, allowing the world to see the development trend of Taiwan’s biomedical industry, witness the diversified development of the industry, and excellent innovative research and development. Achievements and strength demonstrated. This year’s list of winners covers new biotech drugs, CDMOs, immune/cell therapy, regenerative medicine, innovative medical materials, high-end medical materials, medical artificial intelligence, agricultural biotechnology, and healthy food, demonstrating the diversified development and R&D energy of the industry.
Outstanding Biotechnology Industry Award “3 Major Awards” 13 institutions and product technologies won the award
Convener of the Medal Committee and Chairman Zhang Wenchang of Taipei Medical University pointed out that the Outstanding Biotech Industry Award hopes to recognize biotech companies or academic research institutions with outstanding performance and great potential. The Medal Committee convened 15 Taiwanese industry, government, academic and research experts and scholars to form a judging panel. , evaluation and discussion were conducted based on the key criteria of individual awards. After a rigorous selection process, a total of 13 institutions and product technologies finally stood out.
The award-winning manufacturers will be presented with awards and public recognition by the head of the government at the “BIO Asia - Taiwan Asian Biotech Conference” event that will be held next week. The conference will also arrange a press conference for the outstanding award-winning biotech manufacturers on the main agenda. An international exhibition platform to share its successful experience, innovative technologies, etc., to expand the international exposure of outstanding companies, and to make further progress.
The “Outstanding Biotechnology Industry Award” awards include:
Industry Gold Award: To reward excellence in operational performance, development strategy and technological innovation.
Potential Benchmark Award: This award is given to biotechnology companies that have been established in Taiwan for no more than 15 years or have a turnover of less than NT$1 billion in the previous year, with outstanding future development potential and promising prospects.
Annual Innovation Award: To reward the most innovative products or technologies that will be launched or licensed in 2022.
Each award is divided into three categories : pharmaceuticals/regenerative medicine/commissioned development and manufacturing, medical materials/digital medicine/precision medicine, and applied biotechnology/agriculture/food/medical beauty.
Winning the Gold Award for Outstanding Biotechnology Industry, “Litong” grew despite the COVID-19 epidemic.
The biggest highlight among the winners of this year’s “Outstanding Biotechnology Industry Gold Award” is none other than “Litong Co., Ltd.”, which is engaged in the research and product design and development of functional food, animal husbandry and agricultural biotechnology, and is deeply involved in health with health care functions. It has been in the food field for many years and has a cross-international patent layout. When choosing themes, it gives priority to sub-health themes with unique and special markets. Although the world is deeply affected by the COVID-19 epidemic, its revenue is still growing year by year amid this torrent.
“Guoli Biotechnology”, a subsidiary of Litong, recently launched a patented Lactobacillus acidophilus (L. acidophilus) functional probiotic, adding natural yeast B complex, sunshine yeast vitamin D, and natural yeast glucan and other protective nutrients ; As the only regulatory probiotic LT-12 on the market that has been patented by six countries, Lactobacillus paracasei was designed and isolated in Taiwan and produced in the United States. It not only has superior stability, but is also acid-resistant and bile-salt resistant, and can adjust your body constitution. Externally, it upgrades internal protection.
Winner of the Potential Benchmark Award “Angen Biotechnology” develops new drugs and attracts major US manufacturers to sign contracts
Won the “Potential Benchmark Award”, a company with great R&D capabilities and future development potential: “Anji Biotechnology”, focusing on innovative small molecules (Nrf2 activator AJ201, HDAC6 inhibitor AJ302/303, and next-generation androgen degradation accelerators AJ202) New drug development with three main axes, the team is good at new drug topic selection, translational medicine and drug development planning. Despite the impact of the epidemic, in less than two years, it exerted its high-speed team and resource integration capabilities to create mergers and acquisitions with high market value benefit.
In addition, recognizing the effectiveness and therapeutic potential of AJ201, ANGI announced in March that it has signed an exclusive European and American licensing contract with the US-listed biotech new drug company “venue Therapeutics Inc.” for AJ201, a rare disease - Kennedy’s disease small molecule new drug. , with a total authorization amount of up to US$250 million. The success of AJ201’s early clinical authorization has amazed the new drug market for rare diseases. Currently, the second phase of clinical trials of AJ201 has begun to be accepted in six major medical centers in the United States. There will be opportunities to help more in the future. Dorothenic disease patients.
“Taikang Biotech”’s cancer biosimilar drug development received an approval letter from the Taiwan Food and Drug Administration approving the drug license
It is worth mentioning that EIRGASUN, developed by the award-winning biotechnology company “Taikang Biotechnology”, has become the first biosimilar drug independently developed in Taiwan to be approved by the Taiwan Ministry of Health and Welfare, and has also attracted market attention. Taikang Biotechnology’s breast cancer biosimilar drug EG12014 officially received an approval letter from the Taiwan Ministry of Health and Welfare, Food and Drug Administration in May to approve the drug certificate; the drug certificate approved is a frozen crystal injection 150 mg dosage form, which will be used in the control drug He The indications covered by Herceptin include the treatment of patients with early-stage HER2-positive breast cancer and metastatic breast cancer and gastric cancer.
Breast cancer is one of the most common types of female cancer, with approximately 2.32 million cases in 2021, and about 20% of breast cancer patients have “HER2-positive” tumors. Patients with this type of tumor tend to grow faster than HER2-negative tumors. Faster, so getting treatment quickly is crucial.
Cancer is also one of the two major causes of death in the world. Herceptin (main ingredient Trastuzumab) has global sales of US$2.64 billion, and global sales of biosimilar drugs exceed US$4.9 billion; according to Taiwan drug sales data in 2022, Herceptin (trastuzumab) has global sales of US$2.64 billion. With a flat sales value of NT$2.388 billion, it is also among the top five pharmaceutical items in terms of health insurance payment expenditure.
With the first biosimilar drug independently developed in Taiwan being approved by the Taiwan Ministry of Health and Welfare, it is indeed an important milestone for Taiwan’s biotechnology industry and cancer patients. The official launch of EIRGASUN in Taiwan will help increase patients’ access to high-quality, life-improving drugs and save money for the healthcare system.
Finally, Chairman Wu Zhongxun said that all biotechnology companies or innovative technologies with outstanding performance and potential are worthy of encouragement and praise, and can serve as benchmarks for future development, leading more companies and resource investment, and are expected to create a larger scale and higher standard. and beneficial biotechnology industry.
